Rocket Pharmaceuticals Inc (NASDAQ:RCKT) Forecasted to Earn Q1 2021 Earnings of ($0.70) Per Share

Rocket Pharmaceuticals Inc (NASDAQ:RCKT) – Stock analysts at Piper Jaffray Companies issued their Q1 2021 earnings estimates for shares of Rocket Pharmaceuticals in a research note issued on Thursday, November 7th. Piper Jaffray Companies analyst T. Van. Buren anticipates that the biotechnology company will earn ($0.70) per share for the quarter. Piper Jaffray Companies has a “Overweight” rating on the stock. Piper Jaffray Companies also issued estimates for Rocket Pharmaceuticals’ Q2 2021 earnings at ($0.75) EPS and Q3 2021 earnings at ($0.80) EPS.

Several other brokerages also recently weighed in on RCKT. ValuEngine downgraded shares of Rocket Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Cowen restated a “buy” rating on shares of Rocket Pharmaceuticals in a research note on Thursday. Chardan Capital initiated coverage on shares of Rocket Pharmaceuticals in a research note on Tuesday. They issued a “buy” rating and a $30.00 target price for the company. Oppenheimer lowered their target price on shares of Rocket Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating for the company in a research note on Tuesday, August 13th. Finally, William Blair restated a “buy” rating on shares of Rocket Pharmaceuticals in a research note on Tuesday, September 10th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Rocket Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $28.33.

RCKT traded up $1.20 during trading on Friday, hitting $16.36. The stock had a trading volume of 171,500 shares, compared to its average volume of 286,469. The company has a market capitalization of $729.55 million, a PE ratio of -8.66 and a beta of 2.74. Rocket Pharmaceuticals has a twelve month low of $10.75 and a twelve month high of $20.79. The company has a debt-to-equity ratio of 0.18, a quick ratio of 17.48 and a current ratio of 17.48. The stock has a 50 day simple moving average of $13.02 and a two-hundred day simple moving average of $14.19.

Rocket Pharmaceuticals (NASDAQ:RCKT) last announced its earnings results on Thursday, November 7th. The biotechnology company reported ($0.38) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.49) by $0.11.

Several large investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC lifted its stake in shares of Rocket Pharmaceuticals by 1,107.4% during the third quarter. Tower Research Capital LLC TRC now owns 4,250 shares of the biotechnology company’s stock worth $50,000 after buying an additional 3,898 shares during the period. Comerica Bank boosted its holdings in Rocket Pharmaceuticals by 35.2% in the 3rd quarter. Comerica Bank now owns 28,155 shares of the biotechnology company’s stock valued at $363,000 after purchasing an additional 7,329 shares during the last quarter. California Public Employees Retirement System acquired a new position in Rocket Pharmaceuticals in the 3rd quarter valued at about $168,000. Lindbrook Capital LLC boosted its holdings in Rocket Pharmaceuticals by 200.0% in the 3rd quarter. Lindbrook Capital LLC now owns 3,000 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 2,000 shares during the last quarter. Finally, Zeke Capital Advisors LLC boosted its holdings in Rocket Pharmaceuticals by 79.1% in the 3rd quarter. Zeke Capital Advisors LLC now owns 18,326 shares of the biotechnology company’s stock valued at $213,000 after purchasing an additional 8,094 shares during the last quarter. Institutional investors and hedge funds own 96.72% of the company’s stock.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; and leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction It also has additional pre-clinical stage LVV programs include pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption.

Recommended Story: Strike Price

Earnings History and Estimates for Rocket Pharmaceuticals (NASDAQ:RCKT)

Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply